
|Articles|April 1, 2004
HUMAX-CD4 STUDY
Genmab A/S presented data from Phase II HuMax-CD4 studies to treat cutaneous T-cell lymphoma (CTCL) at the 65th annual meeting of the Society for Investigative Dermatology in April. At the time the abstract was completed, 36 patients enrolled in the two ongoing HuMax-CD4 clinical trials were evaluated using the Composite Assessment of Index Lesion Disease Activity (CA) score.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
2
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
5











